checkAd

     120  0 Kommentare Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients - Seite 3

    Contact
    Alexis Nahama, DVM (SVP Corporate Development)
    Email: mediarelations@sorrentotherapeutics.com

    Sorrento and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

    G-MAB, DAR-T, SOFUSA, COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVIDROPS, COVI-MSC, COVITRACK, COVITRACE and COVISTIX are trademarks of Sorrento Therapeutics, Inc.

    SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc.

    ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc.

    All other trademarks are the property of their respective owners.

    2021 Sorrento Therapeutics, Inc. All Rights Reserved.



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients - Seite 3 FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS) in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer